206 related articles for article (PubMed ID: 38602703)
1. Addressing Financial Toxicity in Head and Neck Cancer-A Crucial Imperative.
Mady LJ; Goldberg ZN; de Almeida JR
JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):455-456. PubMed ID: 38602703
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, trends, and demographic characteristics associated with self-reported financial stress among head and neck cancer patients in the United States of America.
Jella TK; Cwalina TB; Sachdev R; Otteson T; Fowler N
Am J Otolaryngol; 2021; 42(6):103154. PubMed ID: 34214715
[TBL] [Abstract][Full Text] [Related]
3. Measuring financial toxicity in head and neck cancer: a systematic review.
Raggini E; Mattavelli D; Zigliani G; Bossi P; Piazza C
Acta Otorhinolaryngol Ital; 2024 Feb; 44(1):1-12. PubMed ID: 38420716
[TBL] [Abstract][Full Text] [Related]
4. Understanding financial toxicity in head and neck cancer survivors.
Mady LJ; Lyu L; Owoc MS; Peddada SD; Thomas TH; Sabik LM; Johnson JT; Nilsen ML
Oral Oncol; 2019 Aug; 95():187-193. PubMed ID: 31345389
[TBL] [Abstract][Full Text] [Related]
5. Patients' perception of the financial impact of head and neck cancer and the relationship to health related quality of life.
Rogers SN; Harvey-Woodworth CN; Hare J; Leong P; Lowe D
Br J Oral Maxillofac Surg; 2012 Jul; 50(5):410-6. PubMed ID: 22000023
[TBL] [Abstract][Full Text] [Related]
6. Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy.
Ma SJ; Iovoli AJ; Attwood K; Wooten KE; Arshad H; Gupta V; McSpadden RP; Kuriakose MA; Markiewicz MR; Chan JM; Hicks WL; Platek ME; Ray AD; Repasky EA; Farrugia MK; Singh AK
Oral Oncol; 2021 Apr; 115():105196. PubMed ID: 33578203
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of human papillomavirus-associated head and neck cancers in the United States.
Coughlan D; Frick KD
Otolaryngol Clin North Am; 2012 Aug; 45(4):899-917. PubMed ID: 22793859
[TBL] [Abstract][Full Text] [Related]
8. Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors.
Baddour K; Kudrick LD; Neopaney A; Sabik LM; Peddada SD; Nilsen ML; Johnson JT; Ferris RL; Mady LJ
Head Neck; 2020 Jun; 42(6):1332-1338. PubMed ID: 32329924
[TBL] [Abstract][Full Text] [Related]
9. Cancer-related financial hardship among head and neck cancer survivors: Risk factors and associations with health-related quality of life.
Lu L; O'Sullivan E; Sharp L
Psychooncology; 2019 Apr; 28(4):863-871. PubMed ID: 30779397
[TBL] [Abstract][Full Text] [Related]
10. Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period.
Egestad H; Nieder C
Int J Circumpolar Health; 2015; 74():26686. PubMed ID: 25623815
[TBL] [Abstract][Full Text] [Related]
11. Treatment costs for patients with head and neck cancer.
Suen JY; Jackson MJ; Porr MJ
Arch Otolaryngol; 1979 Mar; 105(3):160-3. PubMed ID: 420657
[TBL] [Abstract][Full Text] [Related]
12. The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors.
Baddour K; Fadel M; Zhao M; Corcoran M; Owoc MS; Thomas TH; Sabik LM; Nilsen ML; Ferris RL; Mady LJ
Head Neck; 2021 Oct; 43(10):3062-3075. PubMed ID: 34235804
[TBL] [Abstract][Full Text] [Related]
13. Patients' perspective of financial benefits following head and neck cancer in Merseyside and Cheshire.
Rogers SN; Harvey-Woodworth CN; Lowe D
Br J Oral Maxillofac Surg; 2012 Jul; 50(5):404-9. PubMed ID: 21993178
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.
Jansen F; Krebber AM; Coupé VM; Cuijpers P; de Bree R; Becker-Commissaris A; Smit EF; van Straten A; Eeckhout GM; Beekman AT; Leemans CR; Verdonck-de Leeuw IM
J Clin Oncol; 2017 Jan; 35(3):314-324. PubMed ID: 27918712
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of head and neck cancer: a systematic literature review.
Wissinger E; Griebsch I; Lungershausen J; Foster T; Pashos CL
Pharmacoeconomics; 2014 Sep; 32(9):865-82. PubMed ID: 24842794
[TBL] [Abstract][Full Text] [Related]
16. Defining value-driven care in head and neck oncology.
Roman BR; Awad MI; Patel SG
Curr Oncol Rep; 2015 Jan; 17(1):424. PubMed ID: 25416318
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors.
Massa ST; Osazuwa-Peters N; Adjei Boakye E; Walker RJ; Ward GM
JAMA Otolaryngol Head Neck Surg; 2019 Mar; 145(3):239-249. PubMed ID: 30789634
[TBL] [Abstract][Full Text] [Related]
18. Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire.
Hueniken K; Douglas CM; Jethwa AR; Mirshams M; Eng L; Hope A; Chepeha DB; Goldstein DP; Ringash J; Hansen A; Martino R; Li M; Liu G; Xu W; de Almeida JR
Cancer; 2020 Sep; 126(17):4042-4050. PubMed ID: 32603521
[TBL] [Abstract][Full Text] [Related]
19. Using comorbidity indexes to predict costs for head and neck cancer.
Hollenbeak CS; Stack BC; Daley SM; Piccirillo JF
Arch Otolaryngol Head Neck Surg; 2007 Jan; 133(1):24-7. PubMed ID: 17224517
[TBL] [Abstract][Full Text] [Related]
20. The effect of hospital safety-net burden status on short-term outcomes and cost of care after head and neck cancer surgery.
Genther DJ; Gourin CG
Arch Otolaryngol Head Neck Surg; 2012 Nov; 138(11):1015-22. PubMed ID: 23165375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
